3649 results for «383»
3649 results
How to face resistent hypertension: when pharmacological treatment is not an option
19 May 2026 – From EuroPCR 2026
Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.
FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case
19 May 2026 – From EuroPCR 2026
A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.
Lesion preparation was performed with...
TAVI procedural complications - Part 3: vascular complications, coronary issues and more
19 May 2026 – From EuroPCR 2026
This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.
Identifying problems and solving complex anatomies during TAVI
19 May 2026 – From EuroPCR 2026
A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.
Calcified coronary: LIVE Educational Case from Clinique Pasteur - Toulouse, France
20 May 2026 – From EuroPCR 2026
This live educational case from Clinique Pasteur in Toulouse, France, showcases the management of complex calcified coronary lesions through multimodality imaging guidance. It addresses the selection of plaque modification devices and discusses optimal stenting strategies for challenging calcified bifurcation lesions, complemented by live procedural insights and...
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)
08 Apr 2024
Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.
Author
The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction
18 Nov 2024
Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.
Author
NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation
01 Sep 2024
Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.
Author
Author
Author
